Dr. Reddy’s Laboratories has launched Paricalcitol Injection, USP, in 2 mcg, 5 mcg, 10 mcg, a therapeutic equivalent generic version of Zemplar (paricalcitol) Injection in the United States market approved by the US Food & Drug Administration (USFDA).
The Zemplar brand and generic had US sales of approximately $22.5 million MAT for the most recent twelve months ending in July 2016, according to IMS Health. Dr. Reddy’s Paricalcitol Injection is available in 2 mcg, 5 mcg, and 10 mcg, and is the first ANDA product launched in the US market.
Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.
